International Clinical Trial: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with chronic immune thrombocytopenia

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115452) titled 'A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with chronic immune thrombocytopenia' on Dec. 26, 2025.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Condition: Chronic immune thrombocytopenia (ITP)

Intervention: 30mg/30mg group:CID-103 will be administered as an IV infusion. The first dose of CID-103 will be a priming dose. Subjects will then receive weekly doses of C...